- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Breaking Down Treatment and Management Options in Vitiligo
Author(s):
Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.
Last year, the US Food and Drug Administration (FDA) approved ruxolitinib cream 1.5% for the treatment of nonsegmental vitiligo. It became the first FDA-approved drug for restoring pigment in patients with vitiligo.
Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care, and the Dermatology Times® team has compiled a list of treatment and management options for a variety of patient outcomes.
When it comes to vitiligo, patients seeking treatment have a few options that depend on their desired outcomes. They can take 1 of the following routes: repigmentation, depigmentation, or stabilization.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
